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ingston upon Hull and Edgbaston, United Kingdom;
avia, Italy; and Rennes, France
bservational studies can help describe patient outcome, but
nly randomized controlled trials can assess the response to
reatment. All too often, doctors confuse outcome with re-
ponse, and nowhere is this better illustrated than with
ardiac resynchronization therapy (CRT). If someone with
ittle evidence of cardiac disease is implanted with a CRT
evice, he or she will almost certainly have an excellent
utcome, but it would be wrong to attribute this to the
evice. A patient who was otherwise destined to die soon,
ho survived because he or she received CRT, but who had
ittle improvement in symptoms may be considered to have
ad a poor outcome but, nevertheless, has responded to
See page 600
reatment. Differentiation between outcome and response is
endered even more difficult because most patients with
eart failure experience episodes of acute deterioration and
any experience a gradual decline in underlying cardiac
unction that may confound assessment of the benefits of
reatment. Any patient with heart failure who has not
eteriorated might be considered to have benefited from
ntervention. Indeed, this was a definition of treatment re-
ponse used in the CARE-HF (Cardiac Resynchronisation in
eart Failure) trial (Table 1) (1–3). Prevention of sudden
eath in a patient who enjoys a reasonable quality of life is
lso generally regarded as a benefit even if the treatment
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Cardiology, Castle Hill Hospital, Kingston upon Hull,
nited Kingdom; ‡IRCCS Policlinico S. Matteo, Pavia, Italy; §Département deC
ardiologie, Hôpital Pontchaillou, Rennes, France; and the University of Birming-
am, Edgbaston, United Kingdom.oes not improve symptoms and has some side effects.
bservational studies are not very good at assessing the
mportance of the absence of such events.
However, observational studies can be useful. In this issue
f the Journal, Mullens et al. (4) show, in an observational
tudy, that patients who do not appear to have benefited
rom CRT often deteriorate when it is withdrawn (4). This
uggests that in some patients, the benefit from CRT is
trumped” by deterioration in the underlying cardiac dis-
ase. This casts further doubt on the validity of observa-
ional trials that have attempted to predict who needs CRT
sing imaging or the electrocardiogram, as their results are
ighly dependent on the definition of response (5). Para-
oxically, the observations made by Mullens et al. (4)
ndermine the notion that treatment response can be
ssessed reliably in an observational trial.
The mythological patron of medicine was Hermes
Greek) or Mercury (Roman), and many institutions use his
and (the caduceus) as a symbol. He was also the god of
erchants, thieves, and gamblers. Maybe, as a profession,
e are at risk of being as much doctors of “spin” as doctors
f medicine. Doctors are very good at creating myths.
hronic aspirin therapy for coronary artery disease (6),
ntiarrhythmic drugs for ventricular arrhythmias (7,8), re-
ascularization to improve the prognosis of patients with
table coronary disease (9) or for heart failure (10), and tight
lucose regulation for diabetes (11) are but a few examples
f recent or current management concepts, based on belief
ather than on strong evidence, that have been challenged.
uch beliefs, if wrong, may not be considered a large
roblem by a practicing physician, but from the point of
iew of generations of patients who may suffer the conse-
uences of myth-based treatment this may be a disaster.
he CAST (Cardiac Arrhythmia Suppression Trial) study
aved millions of lives by exposing the delusion that sup-
ressing ventricular arrhythmias with class I antiarrhythmic
gents was an essential part of cardiology practice (7,8). We
eed more studies like it. Hopefully, some will show that
he mythology was correct and the treatment really does
ork. However, treating people on the basis of inadequately
ested hypotheses should be abhorrent to all good physi-
ians, even if they are forced to practice this way until freed
y science.
About 8 years ago, several groups of experts gathered to
iscuss the design of trials for CRT. No one had a strong
ationale for which patients to select. Pioneers had developed
he concept that QRS duration was a guide to ventricular
yssynchrony and used it as the basis to select patients for CRT
12,13). The sponsors of large trials have to balance inno-
ation and wise investment. When the COMPANION
Comparison of Medical Therapy, Resynchronization, and
efibrillation Therapies in Heart Failure) (14) and
ARE-HF trials (2,3,15,16) were conceived, there were
nly the results of the MUSTIC (Multisite Stimulation in
ardiomyopathies Study) trial to guide selection criteria
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February 17, 2009:608–11 Cardiac Resynchronization Therapy17). There was a healthy discussion between scientific
roups, each anxious to provide a high-quality trial but each
oping for a positive result. These committees had to
dentify patients at substantial risk of cardiac events to
ustify implanting, at some risk, a device of unknown value.
best-guess set of entry criteria was evolved. Unfortu-
ately, once clinical trial entry criteria are used to formulate
ecommendations, they can become a barrier to progress
ecause the concepts of an absence of evidence of an effect
nd evidence of absence of an effect are often confused.
espite considerable efforts, analyses of the CARE-HF
tudy has failed, as yet, to identify a particular set of patient
haracteristics that lead to clinically important differences in
reatment effect (18,19). The effect of CRT in CARE-HF
as large, suggesting that, by chance, the precise criteria for
esponse had been chosen or, more likely, that the entry
riteria had excluded many patients who would have re-
ponded. We need further randomized trials to find out
hich of the inclusion and exclusion criteria applied in trials
hould be adopted into clinical practice. It is important to
now who CRT does and does not help, but only random-
zed trials can deliver a secure answer in most cases.
For potentially curable diseases, such as infections, it is
ensible to talk about response rates. Heart failure is not
enerally curable—yet (20). It is naïve to think that patients
ith heart failure neatly divide into responders and nonre-
ponders. There will be a spectrum of response. Some
atients will be harmed by CRT, for instance those that get
n infected system. Others may derive no benefit because
hey are too sick or too well and others will have a good
esponse, which in some cases can appear miraculous. As
ith most interventions in clinical practice, there will also be
placebo response. Intercurrent events further complicate
ttempts to predict the course of the disease. However,
arious Definitions of Response Used in the CARE-HF Trial
Table 1 Various Definitions of Response Used in the CARE-HF
M
Survived without unplanned hospitalization for a major cardiovascular event*
Survived (including extension phase)
Survived free of hospitalization for heart failure
Absence of treatment failure at study end†
Components of the Treatment Failure Definition at Study En
Survived but worse NYHA functional class
Survived but requiring increase of furosemide or equivalent by 40 mg/day
Survived but required new use of loop and thiazide diuretics in combination
Death
Mechanistic or Post-Hoc Definiti
Reduction in LV end-systolic volume by 40 ml by 18 months (24)‡
Patient report of MLWHFQ score 35 at 18 months (1)‡
Investigator-assigned NYHA functional class I/II by 18 months (1)‡
Death or unplanned hospitalization for a major cardiovascular event expressed as proportion
esynchronisation in Heart Failure) trial (2,3); ‡by this time 52 deaths had occurred in those assig
CI  confidence interval; HR  hazard ratio; LV  left ventricular; MLWHFQ  Minnesota Livingesponse is also time dependent. Some patients do not appear to respond initially but may respond later, at a time
hen ventricular function and symptoms would have dete-
iorated had they not had the device. Cardiac dyssynchrony
s unlikely to be a fixed entity and probably varies, either in
esponse to stress or as a function of disease progression
5,21–23). The benefit of CRT may not be predictable
efore implantation because the substrate on which it will
ct in the future is not yet present (23). Perhaps it is best to
bandon attempts to define narrowly who will or will not
enefit from CRT and focus instead on optimizing out-
omes (and response) after implantation in all those that
ight benefit.
There is, as yet, no evidence that QRS duration, dyssyn-
hrony, or left ventricular ejection fraction is relevant for
electing patients for CRT. The appropriate trials to find
ut have not been done. We can identify patients who have
ood outcomes without CRT and, therefore, do not need it
nd perhaps a group of patients (e.g., cardiogenic shock)
ho will do badly despite CRT. Everything else is guess
ork, which should not be good enough for us or our
atients.
Analyses of CARE-HF, which is much larger than any
bservational trial, have struggled to identify anything that
redicts the effects of CRT on morbidity, mortality, or
uality of life. Indeed, dyssynchrony predicted a better
rognosis regardless of assigned treatment possibly because
uch patients are more likely to have dilated cardiomyopathy
nd more viable myocardium, both of which are associated
ith a better prognosis (18,19). In observational studies of
RT implantation, patients with dyssynchrony will have a
etter outcome because they have a better intrinsic progno-
is. Whether CRT has an additional benefit remains uncer-
ain. Improvement in cardiac function 3 months after
mplantation of a CRT device is a good sign associated with
Patients With Events (%)
Therapy (n  404) CRT Group (n  409) OR or HR (95% CI; p Value)
80 (44.6%) 250 (61.1%) HR: 0.63 (0.51–0.77), 0.001
49 (61.6%) 308 (75.3%) HR: 0.60 (0.47–0.77), 0.0001
03 (52.7%) 291 (71.1%) HR: 0.54 (0.43–0.68), 0.001
98 (49%) 264 (64.5%) OR: 0.52 (0.32–0.70), 0.0001
rvivors May Have Contributed to More Than 1 Component)
22 (5.5%) 10 (2.4%) OR: 0.44 (0.20–0.98), 0.044
89 (22.0%) 57 (13.9%) OR: 0.56 (0.39–0.82), 0.003
18 (4.5%) 13 (3.2%) OR: 0.67 (0.31–1.44), 0.301
20 (29.7%) 82 (20.0%) OR: 0.59 (0.42–0.82), 0.002
Response in the CARE-HF Trial
18.6% 49.2% 0.001
66 (41.1%) 213 (52.1%) OR: 0.64 (0.48–0.86), 0.002
51 (37.4%) 255 (62.3%) OR: 0.36 (0.27–0.48), 0.0001
ent at main study end; †a prospectively defined secondary end point in the CARE-HF (Cardiac
cardiac resynchronization therapy (CRT) versus 75 deaths in those assigned to the control group.
eart Failure Questionnaire; NYHA  New York Heart Association; OR  odds ratio.Trial
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Cardiac Resynchronization Therapy February 17, 2009:608–11esponse to CRT (19). Patients with ischemic heart disease
ad less improvement in ventricular function than patients
ith dilated cardiomyopathy with CRT and they had a
orse prognosis, but the change in prognosis caused by
RT was similar in patients with or without ischemic heart
isease (24,25).
Of all the variables studied so far in CARE-HF, amino-
erminal pro-brain natriuretic peptide (NT-proBNP) was
he best baseline predictor of outcome (19), bettered only by
T-proBNP measured 3 months after randomization, but
either value predicted the long-term response to CRT.
he absolute improvement in prognosis with CRT was
imilar in patients with values above and below the median
T-proBNP (26). Patients with relatively normal values of
T-proBNP have an excellent prognosis, and treatment
ith CRT may be deferred. On the other hand, patients
ho have extreme elevations of NT-proBNP have a poor
rognosis. Although they may have a large response to
RT, the outcome is likely still to be poor, unless they are
uitable for a heart transplant. The optimal response to
reatment, that is, change in outcome, is to be expected
mong patients at intermediate risk with moderately ele-
ated increases in NT-proBNP. Clinical trialists should
estrain their instinct to enroll populations with high event
ates in whom treatment response is often small. Far better
o design trials that exclude patients at either extreme of risk
ho cannot benefit and find the “sweet-spot” associated
ith large treatment effects (Fig. 1).
In conclusion, the report of Mullens et al. (4) indicates
hat we should be very wary indeed in asserting whether or
Risk
Therapeutic
Benefit
Maximum Therapeutic
Benefit
Too Well To
Benefit
Too Sick To
Benefit
Figure 1 The Goldilocks Effect
When considering treatment for many diseases there will be some patients
who are too well to benefit and will thrive without treatment and others who are
too sick who will die despite intensive management. In between, there will be
a group that obtains the maximum benefit from treatment. This may be likened
to the story of Goldilocks, who found that 1 bowl of porridge was too hot, 1
was too cold, but another was just right. In more scientific terms, it might be
called the risk–benefit parabola or optimal treatment window.ot a patient has responded to CRT. Observational data aresually hard to interpret and translate into clinical practice.
or the time being, stick to the guidelines when selecting
atients for CRT and optimize programming, particularly
trioventricular delay, for those patients who remain symp-
omatic after implantation. We must also ensure that we do
ot confuse outcome with treatment and response to treatment.
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